GlobeImmune starts cancer drug trial

LOUISVILLE – GlobeImmune Inc. has started a clinical trial to investigate the safety and tolerability of a new drug for patients with metastatic cancers.

The company hopes Tarmogen, GI-6207, will treat certain metastatic cancers, types of cancer that spread from one part of the body to another. This is the third Tarmogen product candidate to enter human clinical trials over the last four years.

Dr. James L. Gulley, director of the Clinical Trials Group LTIB at the National Cancer Institute, will be the principal investigator for the Phase I study funded by the institute.

.

Dr. Timothy Rodell, president and chief executive…